التفاصيل البيبلوغرافية
| العنوان: |
Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage |
| المؤلفون: |
Nomoto, Hiroshi, Kito, Kenichi, Iesaka, Hiroshi, Handa, Takahisa, Yanagiya, Shingo, Miya, Aika, Kameda, Hiraku, Cho, Kyu Yong, Takeuchi, Jun, Nagai, So, Sakuma, Ichiro, Nakamura, Akinobu, Atsumi, Tatsuya |
| المصدر: |
Diabetology & Metabolic Syndrome ; volume 15, issue 1 ; ISSN 1758-5996 |
| بيانات النشر: |
Springer Science and Business Media LLC |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Endocrinology, Diabetes and Metabolism, Internal Medicine |
| الوصف: |
Background Pemafibrate has been reported to ameliorate lipid profiles and liver dysfunction. However, which patients derive benefit from the hepatoprotective effects of pemafibrate is unclear. Methods We conducted a sub-analysis of the PARM-T2D study where subjects with type 2 diabetes complicated by hypertriglyceridemia were prospectively treated with pemafibrate or conventional therapies for 52 weeks. From the original cohort, subjects who had metabolic-associated fatty liver disease without changing their treatment regimens for comorbidities were analyzed. Eligible subjects (n = 293) (average age 61.2 ± 11.7 years, 37.5% female) treated with pemafibrate (pemafibrate, n = 152) or controls who did not change their treatment regimens (controls, n = 141) were divided into three groups based on their alanine aminotransferase (ALT) levels: ALT ≤ upper normal limit (UNL) (pemafibrate, n = 65; controls, n = 50), UNL < ALT ≤ 2×UNL (pemafibrate, n = 58; controls, n = 54), and 2×UNL < ALT (pemafibrate, n = 29; controls, n = 27). Results Pemafibrate treatment significantly ameliorated ALT levels (from 29 to 22 U/L, p < 0.001 by Wilcoxon’s signed-rank test) in the total cohort and subjects with high ALT levels (2×ULN < ALT), and improved liver fibrosis as assessed by the Fibrosis-4 index (mean change − 0.05 (95% confidence interval: −0.22 to − 0.02), p < 0.05 versus baseline by the Mann-Whitney U -test and p < 0.05 versus the ALT ≤ UNL group by the Kruskal–Wallis test followed by Dunn’s post-hoc analysis). Conclusions The hepatoprotective effects of pemafibrate were dominant in subjects with type 2 diabetes complicated with liver dysfunction. Trial registration This study was registered with the University Hospital Medical Information Network Center Clinical Trials Registry (UMIN000037385). |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1186/s13098-023-01187-7 |
| DOI: |
10.1186/s13098-023-01187-7.pdf |
| DOI: |
10.1186/s13098-023-01187-7/fulltext.html |
| الإتاحة: |
https://doi.org/10.1186/s13098-023-01187-7Test |
| حقوق: |
https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: |
edsbas.FE855A70 |
| قاعدة البيانات: |
BASE |
